Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Report
|
An overview of M&A trends for the top 150 global pharmaceutical companies during 2008 and 2009 with discussion of the drivers of recent deals, plus case study analysis of key M&As.
Published By Datamonitor
|
17 Dec 2009 |
$11400
|
Report
|
Datamonitor’s report 5EU: Pricing, Reimbursement, and Regulatory Update provides an overview of developments regarding healthcare reforms, drug regulation, and drug pricing and reimbursement in France, Germany, Italy, Spain, and the UK.
Published By Datamonitor
|
28 Oct 2011 |
$1900
|
Report
|
Datamonitor’s report Biosimilars: Regulatory Update provides analysis on key developments in biosimilar regulations globally. It includes an overview of the background behind these events and popular strategic responses.
Published By Datamonitor
|
08 Dec 2011 |
$1900
|
Report
|
An analysis of global sales forecasts for the Branded PharmaVitae Universe during 2011–16.
Published By Datamonitor
|
03 Feb 2012 |
$5700
|
Brief
|
This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.
Published By Datamonitor
|
13 Dec 2010 |
$500
|
Report
|
This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway.
Published By Datamonitor
|
16 Apr 2012 |
$1900
|
Report
|
This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.
Published By Datamonitor
|
18 May 2011 |
$1900
|
Report
|
Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.
Published By Datamonitor
|
16 Jul 2012 |
$1900
|
Report
|
The Surviving Sepsis Campaign has created an increased focus on reducing levels of mortality from sepsis. Eli Lilly/BioCritica’s Xigris has been unable to capitalize on what remains a potentially lucrative therapy area with significant unmet needs.
Published By Datamonitor
|
17 May 2011 |
$1900
|
Report
|
Analysis of the future potential of anticonvulsants market. Includes sales forecasts over 2009-2018 across the seven major markets (US, Japan, France, Germany, Italy, Spain, and the UK) of key marketed brands, generics, and pipeline agents.
Published By Datamonitor
|
08 Oct 2009 |
$15200
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.